The effect of vaccination on Streptococcus pneumoniae resistance

Current Infectious Disease Reports

Volumn 10, Issue 3, 2008, Pages 182-191

  Leibovitz, Eugene ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; BACTERIAL PROTEIN; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; ERYTHROMYCIN; MACROLIDE; PENICILLIN G; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIAL MENINGITIS; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIUM CULTURE; BACTERIUM ISOLATION; CLINICAL FEATURE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DISEASE COURSE; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG USE; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION CONTROL; INFECTION RISK; LENGTH OF STAY; MORBIDITY; MORTALITY; MULTIDRUG RESISTANCE; NONHUMAN; OTITIS MEDIA; PATHOPHYSIOLOGY; POPULATION RESEARCH; PREVALENCE; RECURRENT DISEASE; RESPIRATORY TRACT INFECTION; REVIEW; RHINOPHARYNGITIS; RISK ASSESSMENT; RISK REDUCTION; SEROTYPE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; THORAX RADIOGRAPHY;

EID: 56349119400     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-008-0031-x     Document Type: Review

References (84)

1. American Academy of Pediatrics: Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics 2000, 106:362-366.
2. Advisory Committee on Immunization Practices: Preventing pneumococcal disease among infants and children. MMWR Morb Mort Wkly Rep 2000, 49(RR-9):1-35.
3. Black S, Shinefield H, Fireman B, et al.: Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatric Infect Dis J 2000, 19:187-195.
4. Block SL: Causative pathogens, antibiotic resistance and therapeutic considerations in acute otitis media. Pediatr Infect Dis J 1997, 16:449-456.
5. Jacobs MR, Dagan R, Appelbaum PC, Burch DJ: Prevalence of antimicrobial-resistant pathogens in middle ear fluid: multinational study of 917 children with acute otitis media. Antimicrob Agents Chemother 1998, 42:589-595.
6. Doern GV, Pfaller MA, Kugler K, et al.: Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. Clin Infect Dis 1998, 27:764-770.
7. Dagan R: Clinical significance of resistant organisms in otitis media. Pediatr Infect Dis J 2000, 19:378-382.
8. Sagraves R: Increasing antibiotic resistance: its effect on the therapy for otitis media. J Pediatr Health Care 2002, 16:79-85.
9. Leibovitz E, Raiz S, Piglansly L, et al.: Resistance pattern of middle ear fluid isolates in acute otitis media recently treated with antibiotics. Pediatr Infect Dis J 1998, 17:463-469.
10. Leibovitz E, Dagan R: Otitis media therapy and drug resistance. Part 1: Management principles. Infect Med 2001, 18:212-216.
11. Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg RN: The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003, 52:229-246.
12. Dagan R, Givon-Lavi N, Shkolnik L, et al.: Acute otitis media caused by antibiotic-resistant Streptococcus pneumoniae in Southern Israel: Implication for immunizing with conjugate vaccines. J Infect Dis 2000, 181:1322-1329.
13. Hausdorff WP, Yothers G, Dagan R, et al.: Multinational study of pneumococcal serotypes causing acute otitis media in children. Pediatr Infect Dis J 2002, 21:1008-1016.
14. Joloba ML, Windau A, Bajaksouzian S, et al.: Pneumococcal conjugate vaccine serotypes of Streptococcus pneumoniae isolates and the antimicrobial susceptibility of such isolates in children with otitis media. Clin Infect Dis 2001, 33:1489-1494.
15. Klein JO: Microbiologic efficacy of antibacterial drugs for acute otitis media. Pediatr Infect Dis J 1993, 12:973-975.
16. McIntosh K: Community-acquired pneumonia in children. N Engl J Med 2002, 346:429-437.
17. Rudan I, Tomaskovic L, Boschi-Pinto C, Campbell H: Global estimate of the incidence of clinical pneumonia among children under five years of age. Bull World Health Organ 2004, 82:895-903.
18. Cutts FT, Zaman SM, Enwere G, et al.: Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomized, double blind, placebo-controlled trial. Lancet 2005, 365:1139-1146.
19. Juven T, Mertsola J, Toikka P, et al.: Clinical profile of serologically diagnosed pneumococcal pneumonia. Pediatr Infect Dis J 2001, 20:1028-1033.
20. Michelow IC, Olsen K, Losano J, et al.: Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics 2004, 113:701-707.
21. Byington CL, Samore MH, Stoddard GJ, et al.: Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: emergence of nonvaccine serogroups. Clin Infect Dis 2005, 41:21-29.
22. Whitney CG, Farley MM, Hadler J, et al.: Increasing prevalence of multidrug resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000, 343:1917-1924.
23. Kaplan SL, Mason EO Jr, Barson WJ, et al.: Outcome of invasive infections outside the central nervous system caused by Streptococcus pneumoniae isolates nonsusceptible to ceftriaxone in children treated with beta-lactam antibiotics. Pediatr Infect Dis J 2001, 20:392-396.
24. Feikin DR, Schuchat A, Kolczak M, et al.: Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance: 1995-1997. Am J Public Health 2000, 90:223-229.
25. Gay K, Baughman W, Miller Y, et al.: The emergence of Streptococcus pneumoniae resistant to macrolide antimicrobial agents: a six-year population-based assessment. J Infect Dis 2000, 182:1417-1424.
26. Hyde TB, Gay K, Stephens DS, et al.: Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 2001, 286:1857-1862.
27. Stephens DS, Zughaier SM, Whitney CG, et al.: Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment. Lancet 2005, 365:855-863.
28. Fuller JD, McGeer A, Low DE: Drug-resistant pneumococcal pneumonia: clinical relevance and approach to management. Eur J Clin Microbiol 2005, 24:780-788.
29. Lujan M, Gallego M, Fontanals D, et al.: Prospective observational study of bacteremic pneumococcal pneumonia: effect of discordant therapy on mortality. Crit Care Med 2004, 32:625-631.
30. Tan TQ, Mason BO Jr, Barson WJ, et al.: Clinical characteristics and outcome of children with pneumonia attributable to penicillin-susceptible and penicillin-non-susceptible Steptococcus pneumoniae. Pediatrics 1998, 102:1369-1375.
31. Paganini H, Guinzau JR, Hernandez C, et al.: Comparative analysis of outcome and clinical features in children with pleural empyema caused by penicillin-nonsusceptible and penicillin-susceptible Streptococcus pneumoniae. Int J Infect Dis 2001, 5:86-88.
32. Lee GM, Harper MB: Risk of bacteremia for febrile young children in the post Haemophilus influenzae type B era. Arch Pediatr Adolesc Med 1999, 152:624-628.
33. Tan TQ: Antibiotic resistant infections due to Streptococcus pneumoniae: impact on therapeutic options and clinical outcome. Curr Opin Infect Dis 2003, 16:271-277.
34. Butler JC, Breiman RF, Lipman HB, et al.: Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978-1994: implications for development of a conjugate vaccine. J Infect Dis 1995, 171:885-889.
35. Black S, France EK, Isaacman D, et al.: Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2007, 26:771-777.
36. Turett GS, Blum S, Fazal BA, et al.: Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence. Clin Infect Dis 1999, 29:321-327.
37. Buckingham SC, McCullers JA, Lujan-Zilberman J, et al.: Pneumococccal meningitis in children: relationship of antibiotic resistance to clinical characteristics and outcomes. Pediatr Infect Dis J 2001, 20:837-643.
38. Fiore AE, Moroney JF, Farley MM, et al.: Clinical outcome of meningitis caused by Streptococcus pneumoniae in the era of antibiotic resistance. Clin Infect Dis 2000, 30:71-77.
39. Bogaert D, De Groat R, Hermans PW: Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 2004, 4:144-154.
40. Brueggemann AB, Griffiths DT, Meats E, et al.: Clonal relationship between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential. J Infect Dis 2003, 187:1424-1432.
41. Fireman B, Black SB, Shinefield HR, et al.: Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J 2003, 22:10-16.
42. Eskola J, Kilpi T, Palmu A, et al.: Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001, 344:403-409.
43. Dagan R, Sikuler-Cohen M, Zamir O, et al.: Effect of a conjugate vaccine on the occurrence of respiratory infections and antibiotic use in day-care center attendees. Pediatr Infect Dis J 2001, 20:951-958.
44. Prymula R, Peeters P, Chrobok V, et al.: Pneumococcal capsular polysaccharide conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomized double-blind efficacy study. Lancet 2006, 367:740-748.
45. Veenhoven R, Bogaert D, Uiterwaal C, et al.: Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomized study. Lancet 2003, 361:2189-2195.
46. Casey J, Pichichero ME: Changes in frequency and pathogens causing acute otitis media in 1995-2003. Pediatr Infect Dis J 2004, 23:824-828.
47. Block SL, Hedrick J, Harrison CJ, et al.: Community-wide vaccination with the heptavalent pneumococcal conjugate alters the microbiology of acute otitis media. Pediatr Infect Dis J 2004, 23:829-833.
48. Poehling KA, Lafleur BJ, Szilagyi PG, et al.: Population-based impact of pneumococcal conjugate vaccine in young children. Pediatrics 2004, 114:755-761.
49. Poehling KA, Szilagyi PG, Grijalva CG, et al.: Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. Pediatrics 2007, 119:707-715.
50. Roddy MG, Glazier SS, Agrawal D: Pediatric mastoiditis in the pneumococcal conjugate vaccine era. Symptom duration guides empiric antimicrobial therapy. Pediatr Emerg Care 2007, 23:779-784.
51. Brook I, Foote A, Hausfeld JN: Frequency of recovery of pathogens causing acute maxillary sinusitis in adults before and after introduction of vaccination with the 7-valent pneumococcal vaccine. J Med Microbiol 2006, 55:943-946.
52. Brook I, Gober AE: Frequency of recovery of pathogens from the nasopharynx of children with acute maxillary sinusitis before and after the introduction of vaccination with the 7-valent pneumococcal vaccine. Int J Pediatr Otorhinolaryngol 2007, 71:575-579.
53. Black SB, Shinefield HR, Ling S, et al.: Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 2002, 21:810-815.
54. Madhi SA, Kuwanda L, Cutland C, Klugman KP: The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and-uninfected children. CLin Infect Dis 2005, 40:1511-1518.
55. Madhi SA, Klugman KP: A role for Streptococcus pneumoniae in virus-associated pneumonia. Nature Medicine 2004, 10:611-813.
56. Grijalva CG, Nuorti JP, Arbogast PG, et al.: Decline in pneumonia admissions after routine childhood immunization with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007, 369:1179-1186.
57. Hansen J, Black S, Shinefield H, et al.: Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia. Pediatr Infect Dis J 2006, 25:779-781.
58. Byington CL, Korgenski K, Daly J, et al.: Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema. Pediatr Infect Dis J 2006, 25:250-254.
59. O'Brien KL, Moulton LH, Reid R, et al.: Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomized trial. Lancet 2003, 362:355-361.
60. Whitney CG, Pilishvili T, Farley MM, et al.: Effectiveness of seven-valent pneumococcal conjugate vaccine against pneumococcal disease: a matched case-control study. Lancet 2006, 368:1495-1502.
61. Poehling KA, Talbot TR, Griffin MR, et al.: Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 2006, 295:1668-1674.
62. Dagan R, Melamed R, Muallem M, et al.: Reduction of nasopharyngeal carriage during the second year of life by a heptavalent conjugate pneumococcal vaccine. J Infect Dis 1996, 174:1271-1278.
63. Dagan R, Givon-Lavi N, Zamir O, et al.: Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine in toddlers attending day care centers. J Infect Dis 2002, 185:927-936.
64. Dagan R, Givon-Lavi N, Zamir O, Fraser D: Effect of a nonvalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day care centers. Pediatr Infect Dis J 2003, 22:532-539.
65. Givon-Lavi N, Fraser D, Dagan R: Vaccination of day-care center attendees reduces carriage of Streptococcus pneumoniae among their younger siblings. Pediatr Infect Dis J 2003, 22:524-532.
66. Ghaffar F, Barton T, Lozano J, et al.: Effect of the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae in the first 2 years of life. Clin Infect Dis 2004, 39:930-938.
67. Frazao N, Brito-Avo A, Simas C, et al.: Effect of the seven-valent conjugate pneumococcal vacine on the carriage and drug resistance of Streptococcus pneumoniae in healthy children attending day-care centers in Lisbon. Pediatr Infect Dis J 2005, 24:243-252.
68. McCraig LF, Besser RF, Hughes JM: Antimicrobial drug prescription in ambulatory care setting, United States, 1992-2000. Emerg Infect Dis 2003, 9:432-437.
69. Dagan R, Barkai G, Leibovitz E, et al.: Will reduction of antibiotic use reduce antibiotic resistance? The pneumococcus paradigm. Pediatr Infect Dis J 2006, 25:981-986.
70. Cohen R, Levy C, de La Rocque F, et al.: Impact of pneumococcal conjugate vaccine and of reduction of antibiotic use on nasopharyngeal carriage of nonsusceptible pneumococci in children with acute otitis media. Pediatr Infect Dis J 2006, 25:1001-1007.
71. Pelton SI, Loughlin AM, Marchant CD: Seven valent pneumococcal conjugate vaccine immunization in two Boston communities. Changes in serotypes and antimicrobial susceptibility among Streptococcus pneumoniae isolates. Pediatr Infect Dis J 2004, 23:1015-1022.
72. Moore MR, Hyde TB, Hennessy TW, et al.: Impact of a conjugate vaccine on community-wide carriage of nonsusceptible Streptococcus pneumoniae in Alaska, J Infect Dis 2004, 190:2031-2038.
73. Byington CL, Samore MH, Stoddard GJ, et al.: Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain West: emergence of nonvaccine serogroups. Clin Infect Dis 2005, 41:21-29.
74. Pia R, Moore MR, Pilishvili T, et al.: Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J Infect Dis 2005, 192:1988-1995.
75. Kyaw MH, Lynfield R, Schaffner W, et al.: Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumonia. N Engl J Med 2006, 354:1455-1463.
76. Farrell DJ, Klugman KP, Pichichero M: Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr Infect Dis J 2007, 26:123-128.
77. Messina AF, Katz-Gaynor K, Barton T, et al.: Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005. Pediatr Infect Dis J 2007, 26:461-467.
78. O'Brien KL, Dagan R: The potential indirect effect of conjugate pneumococcal vaccines. Vaccine 2003, 21:1815-1825.
79. Porat N, Barkai G, Jacobs MR, et al.: Four antibiotic-resistant Streptococcus pneumoniae clones unrelated to the pneumococcal conjugate vaccine serotypes, including 2 new serotypes, causing acute otitis media in southern Israel. J Infect Dis 2004, 189:385-392.
80. Porat N, Arguedas A, Spratt BG, et al.: Emergence of penicillin-nonsusceptible Streptococcus pneumoniae clones expressing serotypes not present in the antipneumococcal conjugate vaccine. J Infect Dis 2004, 190:2154-2161.
81. Pelton SI, Huot H, Finkelstein JA, et al.: Emergence of 19A as virulent and multidrug resistant pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J 2007, 26:468-472.
82. Pichichero ME, Casey JR: Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. JAMA 2007, 298:1772-1778.
83. Klugman KP, McGee L: Resurgence of the multiresistant pneumococcus in the United States: a commentary. Pediatr Infect Dis J 2007, 26:473-474.
84. Dagan R, Givon-Lavi N, Leibovitz E, Porat N: Increased importance of antibiotic-resistant Streptococcus pneumoniae serotype 19A in acute otitis media occurring before introduction of 7-valent pneumococcal conjugate vaccine in southern Israel [abstract G-1001]. Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; September 17-20, 2007.